Alerta

NANOPARTICLES COMPRISING A FUNCTIONAL AGENT AND METHOD OF PREPARATION AND USE THEREOF

Resumen de: WO2026039800A1

This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G/P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

NANOCARRIER COMPOSITIONS AND METHODS FOR ENHANCED CAR-T THERAPY

Resumen de: WO2026039075A1

Methods for enhancing CAR-T or CAR-M cell activity by modulating (e.g., activating or inhibiting) cytotoxic activity of the CAR cells over time to speed up or delay killing activity of the cells. Enhanced CAR-T or CAR-M cells prepared according to methods. Therapeutic compositions and treatment methods, such as for treating cancers, using the enhanced CAR-T or CAR-M cells. The enhanced CAR-T or CAR-M cells comprise drug-loaded nanoparticles or nanocarriers comprising a cell-penetrating peptide (WTAS or rp-182) or a fragment thereof and a modified poly(P-amino ester) (PBAE) polymer associated or assembled with one or more cell modulating agents. The cell modulating agents are released into the cytoplasm to thereby modulate the activity of the enhanced CAR-T cells or CAR-M cells.

RNA APTAMER CONJUGATES AND USES THEREOF

Resumen de: WO2026039717A1

Pharmaceutical compositions and compounds comprising a phosphorothioated CpG oligodeoxynucleotide linked to a DNA oligonucleotide that is hybridized an RNA aptamer are useful in methods of treating cancer (such as leukemia) and methods of inhibiting DNA methyltransferase. In embodiments, the RNA aptamer binds to an intracellular target such as DNMT1, NF-kB, RUNX1, MYC, MYB, ETS, PAX5, MDM2, F0XM1, PU.l, STAT3, STATS. STAT6, FAD, ATP5B, or beta-catenin.

IRON OXIDE-CERIA NANOPARTICLE, IRON OXIDE-CERIA NANOSTRUCTURE AND IRON OXIDE-CERIA NANOCOMPOSITE

Resumen de: WO2026038873A1

An iron oxide-ceria nanoparticle, an iron oxide-ceria nanostructure and an iron oxide-ceria nanocomposite are provided. The iron oxide-ceria nanoparticle comprises iron oxide and ceria. The iron oxide-ceria nanostructure comprises an inorganic support and a plurality of iron oxide-ceria nanoparticles dispersed in the inorganic support. The iron oxide-ceria nanocomposite comprises: an inorganic support; a plurality of iron oxide-ceria nanoparticles dispersed in the inorganic support; and a polymer layer that encompasses the inorganic support.

BRANCHED POLY(β-AMINO ESTER), AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026037345A1

The present disclosure relates to a functionalized targeted branched poly(β-amino ester), a nanoparticle based thereon, a preparation method therefor, and the use thereof. Particularly, the functionalized targeted branched poly(β-amino ester) provided in the present disclosure is capable of effectively delivering biomolecules, particularly functional biomolecules for treating and/or preventing various diseases and conditions.

STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF

Resumen de: WO2026036299A1

Provided in the present invention are a steroid-cationic lipid compound having a structure as shown in formula (I) and the use thereof. The compound can be used in the preparation of a lipid nanoparticle (LNP) for delivering a therapeutic agent and/or a preventive agent. The LNP prepared using the steroid-cationic lipid compound of the present invention has relatively good stability and transfection efficiency. The use of the LNP for delivering a nucleic acid, e.g., an mRNA, can realize efficient and stable delivery of biologically active substances to target cells or organs, and can induce a high level of specific antibody responses and cellular immune responses in experimental animals. Moreover, the compound has better safety.

LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID DRUG, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2026036296A1

A lipid nanoparticle composition for nucleic acid drug delivery, a preparation method therefor, and use thereof. A composition prepared by mixing a steroid-cationic lipid compound with an auxiliary phospholipid and a polyethylene glycol-modified phospholipid has relatively good stability and transfection efficiency. By using lipid nanoparticles for delivering a nucleic acid, such as mRNA, a nucleic acid drug can be efficiently and stably delivered to a target cell or organ. Moreover, such LNPs can be used for the atomized inhalation administration of mRNA and the development of lyophilized formulations of mRNA. A relatively high specific antibody response can be induced in experimental animals, and the compound has better safety.

GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES

Resumen de: US20260048152A1

The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic metal cation selected from ZrO2+, and of an organic active ingredient anion selected from gemcitabine monophosphate or gemcitabine triphosphate.

METAL-CHELATED POLYPHENOL COMPLEX NANOPARTICLE, DRUG-LIPID PARTICLE, PREPARATION METHODS FOR THE SAME, AND USES THEREOF

Resumen de: US20260048142A1

The disclosure relates to the technical field of biological medicines, and particularly provides a metal-chelated polyphenol complex nanoparticle, a drug-lipid particle, preparation methods for the same, and the uses thereof. The present disclosure provides a metal-chelated polyphenol complex as a carrier for drugs for stability, delivery and the like, so that it interacts with other carriers to form a metal-chelated polyphenol complex nanoparticle for effective administration of negatively charged drug. High-efficiency systemic drug delivery can be achieved, while toxicity is significantly reduced compared to LNP containing cationic or ionizable lipids, enabling safe and effective treatment of diseases or disorders.

NANOPARTICLES COMPRISING A FUNCTIONAL AGENT AND METHOD OF PREPARATION AND USE THEREOF

Resumen de: US20260048141A1

This disclosure relates to polyethylene glycol (PEG)-functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G/P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

SELF-THERAPEUTIC DRUG DELIVERY SYSTEM FOR NEURODEGENERATIVE DISEASES

Resumen de: US20260048128A1

The subject invention pertains to a novel composition comprising a self-therapeutic metal nanoparticle core coated with a hydrophilic polymer, and optionally a therapeutic agent linked to the polymer. The linker comprises functional groups that can bind to both the metal core and the polymer. The subject invention further discloses a method for treating HD in a subject comprising administering an effective amount of the composition to a subject with HD. The composition exhibits self-therapeutic properties when administered to patients with Huntington's disease. Additionally, the invention comprises a method for synthesizing gold nanoparticles for treating Huntington's disease. This method comprises conjugating gold nanoparticles with polyethylene glycol (PEG) and attaching a therapeutic agent via a linker to the PEG. This enables targeted delivery of the therapeutic agent to its therapeutic targets.

ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF

Resumen de: WO2024216279A2

Disclosed herein is an analgesic composition comprising a nanoparticle and/or a microparticle that comprises a charged lipid and/or a supporting lipid; where the charged lipid comprises an electrically charged group. Disclosed herein too is a method of reducing joint inflammation, swelling and/or pain in a subject, the method comprising administering a therapeutically effective amount an analgesic composition to the subject; where the analgesic composition comprises a nanoparticle and/or a microparticle that comprises a charged lipid and/or a supporting lipid; where the charged lipid comprises an electrically charged group.

LIPID NANOPARTICLES FOR DELIVERY OF AGENTS

Resumen de: CN120936389A

The present disclosure provides compositions capable of delivering a load (including therapeutic agents, e.g., RNA) to organs or tissues other than the liver, lung and spleen (e.g., brain, heart, kidney and muscular tissue). More specifically, the composition comprises a plurality of lipid particles comprising an agent, a cationic lipid, and an ionizable lipid.

ＨＳＣ特異的抗体結合脂質ナノ粒子及びその使用

Resumen de: AU2024214423A1

Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid. nanoparticles.

肺疾患を治療するための組成物及び方法

Resumen de: AU2024213596A1

A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary' condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.

外用剤

Resumen de: JP2026026813A

【課題】副作用のリスクが小さく、疼痛、アレルギー性鼻炎、眼疲労、又は肥満症の緩和に有効な外用剤を提供する。【解決手段】疼痛、アレルギー性鼻炎、眼疲労、又は肥満症の緩和に用いられる、ナノダイヤモンドを有効成分として含有する外用剤。【選択図】なし

LYME DISEASE VACCINES

Resumen de: WO2024215721A1

This disclosure provides methods and compositions related to messenger ribonucleic acid (mRNA) vaccines for Lyme disease and related methods of prevention. The mRNA vaccines comprise an mRNA comprising an open reading frame(s) encoding for a protein comprising a Borrelia outer surface protein A (OspA) extracellular domain. In some aspects of the disclosure, the mRNA vaccines comprise mRNA polynucleotides collectively encoding for at least seven different Borrelia outer surface protein A (OspA) extracellular domains.

PREPARATION METHOD FOR NANOBODY TARGETING TISSUE FACTOR AND CONJUGATE AND USE THEREOF

Resumen de: EP4696714A1

Disclosed are a new nanobody (Nb) targeting a tissue factor (TF) and a nanobody-drug conjugate (NDC), a preparation method therefor and the use thereof. The monoclonal nanobody and the corresponding NDC can efficiently and high-specifically bind to a purified TF protein and a TF on the surface of various TF abnormally expressed tumor cells, have a high affinity and a low immunogenicity, and have a significant anti-tumor effect in vivo and in vitro.

NANOPARTICLES OF MYCOPHENOLIC ACID PRODRUG MOLECULES AND THERAPEUTIC USE THEREOF

Resumen de: AU2024255212A1

A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.

POLYSIALIC ACID-POLYMER CONJUGATE AND NANOPARTICLE

Resumen de: MX2025012226A

Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.

LIPID NANOPARTICLES TARGETING SPLEEN

Resumen de: EP4696305A1

The present application relates to lipid nanoparticles comprising steroid compound, as well as the preparation and uses of such lipid nanoparticles. Such lipid nanoparticles are useful in the delivery of payloads, such as nucleic acids, in vivo to non-hepatic organs (e.g., spleen) for the treatment or prevention of certain diseases or disorders, particularly spleen diseases.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: AU2024251515A1

The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.

LIPID NANOPARTICLES FOR GENE EDITING SYSTEMS

Resumen de: WO2024215959A2

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction with an LNP-encapsulated CRISPR/Cas9 gene editing system.

METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES

Resumen de: AU2024250699A1

The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.

COMPOSITION, VACCINE AND METHOD FOR TREATING INFLUENZA A

Nº publicación: EP4694923A2 18/02/2026

Solicitante:

ACADEMIA SINICA [TW]
UNIV NAT TAIWAN [TW]
Academia Sinica,
National Taiwan University

Resumen de: TW202444409A

The present disclosure provides a composition comprising a polymeric nanoparticle encapsulating an antigen and an agonist, wherein the antigen is M2e peptide. The composition may induce the immune response to influenza A. A method for inducing immune response to influenza A is also provided.